Skip to main
HROW

HROW Stock Forecast & Price Target

HROW Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Harrow is a company with a strong foundation in delivering pharmaceutical products for eye care, with established relationships and a new drug, MELT, that has potential for cross-selling and growth. While regulatory challenges and potential changes in expenses and regulations may impact financial projections, the company is still expected to see significant growth in the near future with the adoption of their current products, such as IHEEZO, and the submission of a New Drug Application for MELT-300, which could replace opioid-based sedation in cataract surgeries.

Bears say

Harrow is a company that specializes in the development and commercialization of ophthalmic pharmaceutical products, particularly for the treatment of various eye conditions. Despite recent profitability, the company has a history of operating losses and may struggle to sustain profitability in the future due to limited capital. Furthermore, the company faces tough competition in the eye care market and may need to raise additional funds to support its operations and launch new products. Given the challenges the company faces, it is likely to have a negative impact on its stock performance in the long run.

HROW has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harrow Health Inc (HROW) Forecast

Analysts have given HROW a Strong Buy based on their latest research and market trends.

According to 7 analysts, HROW has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harrow Health Inc (HROW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.